Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
Bruton’s tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-cell survival and proliferation. Designing ne...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Public Library of Science (PLoS)
2023-01-01
|
| Schriftenreihe: | PLoS ONE |
| Online-Zugang: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470882/?tool=EBI |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|